Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Cidara Therapeutics, Inc is a biotechnology business based in the US. Cidara Therapeutics shares (CDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cidara Therapeutics employs 68 staff and has a trailing 12-month revenue of around USD$26.8 million.
|Latest market close||USD$2.4|
|52-week range||USD$1.3 - USD$4.34|
|50-day moving average||USD$3.0406|
|200-day moving average||USD$3.3663|
|Wall St. target price||USD$6.61|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.143|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||4.35%|
|1 month (2020-11-04)||-3.23%|
|3 months (2020-09-04)||-22.08%|
|6 months (2020-06-04)||-33.88%|
|1 year (2019-12-04)||-3.61%|
|2 years (2018-12-04)||-34.43%|
|3 years (2017-12-04)||-69.81%|
|5 years (2015-12-04)||-85.82%|
|Revenue TTM||USD$26.8 million|
|Gross profit TTM||USD$-25,486,000|
|Return on assets TTM||-43.77%|
|Return on equity TTM||-127.41%|
|Market capitalisation||USD$127.2 million|
TTM: trailing 12 months
There are currently 2.1 million Cidara Therapeutics shares held short by investors – that's known as Cidara Therapeutics's "short interest". This figure is 0.1% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Cidara Therapeutics shares can be evaluated.
Cidara Therapeutics's "short interest ratio" (SIR) is the quantity of Cidara Therapeutics shares currently shorted divided by the average quantity of Cidara Therapeutics shares traded daily (recently around 257068.51168512). Cidara Therapeutics's SIR currently stands at 8.13. In other words for every 100,000 Cidara Therapeutics shares traded daily on the market, roughly 8130 shares are currently held short.
However Cidara Therapeutics's short interest can also be evaluated against the total number of Cidara Therapeutics shares, or, against the total number of tradable Cidara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cidara Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cidara Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0559% of the tradable shares (for every 100,000 tradable Cidara Therapeutics shares, roughly 56 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cidara Therapeutics.
Find out more about how you can short Cidara Therapeutics stock.
We're not expecting Cidara Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Cidara Therapeutics's shares have ranged in value from as little as $1.3 up to $4.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cidara Therapeutics's is 1.8423. This would suggest that Cidara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.